First, the neuropathologically verified cases of CJD were lacking in our study and most of the subjects enrolled were clinically probable CJD patients with no 14‐3‐3 protein values, which makes it difficult to compare the diagnostic power between classic biomarker and novel indicators based on ATN framework. This evidence concerns the gene YWHAQ and Creutzfeldt Jacob disease.